Acetylcholinesterase inhibitors attenuate angiogenesis

Ryohei Miyazaki, Toshihiro Ichiki, toru hashimoto, Jiro Ikeda, Aya Kamiharaguchi, Eriko Narabayashi, Hirohide Matsuura, Kotaro Takeda, Kenji Sunagawa

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Donepezil {(RS)-2-[(1-benzyl-4-piperidyl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one} is a reversible acetylcholinesterase inhibitor and used for treatment of patients with AD (Alzheimer's disease). Recent studies showed that treatment with donepezil reduced production of inflammatory cytokines in PBMCs (peripheral blood mononuclear cells). It was also reported that musclederived inflammatory cytokines play a critical role in neovascularization in a hindlimb ischaemia model. We sought to determine whether donepezil affects angiogenesis. A hindlimb ischaemia model was created by unilateral femoral artery ligation. Blood flow recovery examined by laser Doppler perfusion imaging and capillary density by immunohistochemical staining of CD31-positive cells in the ischaemic hindlimb were significantly decreased in donepezil- and physostigmine-treated mice comparedwith control mice after 2 weeks. Donepezil reduced expression of IL (interleukin)-1β and VEGF (vascular endothelial growth factor) in the ischaemic hindlimb. Intramuscular injections of IL-1β to the ischaemic hindlimb reversed the donepezil-induced VEGF down-regulation and the anti-angiogenic effect. Hypoxia induced IL-1β expression in C2C12 myoblast cells, which was inhibited by pre-incubation with ACh (acetylcholine) or LY294002, a PI3K (phosphoinositide 3-kinase) inhibitor. Donepezil inhibited phosphorylation of Akt [also known as PKB (protein kinase B)], a downstream kinase of PI3K, in the ischaemic hindlimb. These findings suggest that cholinergic stimulation by acetylcholinesterase inhibitors suppresses angiogenesis through inhibition of PI3K-mediated IL-1β induction, which is followed by reduction of VEGF expression. Acetylcholinesterase inhibitor may be a novel anti-angiogenic therapy.

Original languageEnglish
Pages (from-to)241-249
Number of pages9
JournalClinical Science
Volume123
Issue number4
DOIs
Publication statusPublished - Aug 1 2012

Fingerprint

Cholinesterase Inhibitors
Hindlimb
Interleukin-1
1-Phosphatidylinositol 4-Kinase
Vascular Endothelial Growth Factor A
Ischemia
Cytokines
Proto-Oncogene Proteins c-akt
Physostigmine
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
Perfusion Imaging
Myoblasts
Intramuscular Injections
Femoral Artery
donepezil
Cholinergic Agents
Acetylcholine
Ligation
Blood Cells
Alzheimer Disease

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Miyazaki, R., Ichiki, T., hashimoto, T., Ikeda, J., Kamiharaguchi, A., Narabayashi, E., ... Sunagawa, K. (2012). Acetylcholinesterase inhibitors attenuate angiogenesis. Clinical Science, 123(4), 241-249. https://doi.org/10.1042/CS20110633

Acetylcholinesterase inhibitors attenuate angiogenesis. / Miyazaki, Ryohei; Ichiki, Toshihiro; hashimoto, toru; Ikeda, Jiro; Kamiharaguchi, Aya; Narabayashi, Eriko; Matsuura, Hirohide; Takeda, Kotaro; Sunagawa, Kenji.

In: Clinical Science, Vol. 123, No. 4, 01.08.2012, p. 241-249.

Research output: Contribution to journalArticle

Miyazaki, R, Ichiki, T, hashimoto, T, Ikeda, J, Kamiharaguchi, A, Narabayashi, E, Matsuura, H, Takeda, K & Sunagawa, K 2012, 'Acetylcholinesterase inhibitors attenuate angiogenesis', Clinical Science, vol. 123, no. 4, pp. 241-249. https://doi.org/10.1042/CS20110633
Miyazaki R, Ichiki T, hashimoto T, Ikeda J, Kamiharaguchi A, Narabayashi E et al. Acetylcholinesterase inhibitors attenuate angiogenesis. Clinical Science. 2012 Aug 1;123(4):241-249. https://doi.org/10.1042/CS20110633
Miyazaki, Ryohei ; Ichiki, Toshihiro ; hashimoto, toru ; Ikeda, Jiro ; Kamiharaguchi, Aya ; Narabayashi, Eriko ; Matsuura, Hirohide ; Takeda, Kotaro ; Sunagawa, Kenji. / Acetylcholinesterase inhibitors attenuate angiogenesis. In: Clinical Science. 2012 ; Vol. 123, No. 4. pp. 241-249.
@article{70211c190a1044d88c57a6b9319ec5ca,
title = "Acetylcholinesterase inhibitors attenuate angiogenesis",
abstract = "Donepezil {(RS)-2-[(1-benzyl-4-piperidyl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one} is a reversible acetylcholinesterase inhibitor and used for treatment of patients with AD (Alzheimer's disease). Recent studies showed that treatment with donepezil reduced production of inflammatory cytokines in PBMCs (peripheral blood mononuclear cells). It was also reported that musclederived inflammatory cytokines play a critical role in neovascularization in a hindlimb ischaemia model. We sought to determine whether donepezil affects angiogenesis. A hindlimb ischaemia model was created by unilateral femoral artery ligation. Blood flow recovery examined by laser Doppler perfusion imaging and capillary density by immunohistochemical staining of CD31-positive cells in the ischaemic hindlimb were significantly decreased in donepezil- and physostigmine-treated mice comparedwith control mice after 2 weeks. Donepezil reduced expression of IL (interleukin)-1β and VEGF (vascular endothelial growth factor) in the ischaemic hindlimb. Intramuscular injections of IL-1β to the ischaemic hindlimb reversed the donepezil-induced VEGF down-regulation and the anti-angiogenic effect. Hypoxia induced IL-1β expression in C2C12 myoblast cells, which was inhibited by pre-incubation with ACh (acetylcholine) or LY294002, a PI3K (phosphoinositide 3-kinase) inhibitor. Donepezil inhibited phosphorylation of Akt [also known as PKB (protein kinase B)], a downstream kinase of PI3K, in the ischaemic hindlimb. These findings suggest that cholinergic stimulation by acetylcholinesterase inhibitors suppresses angiogenesis through inhibition of PI3K-mediated IL-1β induction, which is followed by reduction of VEGF expression. Acetylcholinesterase inhibitor may be a novel anti-angiogenic therapy.",
author = "Ryohei Miyazaki and Toshihiro Ichiki and toru hashimoto and Jiro Ikeda and Aya Kamiharaguchi and Eriko Narabayashi and Hirohide Matsuura and Kotaro Takeda and Kenji Sunagawa",
year = "2012",
month = "8",
day = "1",
doi = "10.1042/CS20110633",
language = "English",
volume = "123",
pages = "241--249",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",
number = "4",

}

TY - JOUR

T1 - Acetylcholinesterase inhibitors attenuate angiogenesis

AU - Miyazaki, Ryohei

AU - Ichiki, Toshihiro

AU - hashimoto, toru

AU - Ikeda, Jiro

AU - Kamiharaguchi, Aya

AU - Narabayashi, Eriko

AU - Matsuura, Hirohide

AU - Takeda, Kotaro

AU - Sunagawa, Kenji

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Donepezil {(RS)-2-[(1-benzyl-4-piperidyl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one} is a reversible acetylcholinesterase inhibitor and used for treatment of patients with AD (Alzheimer's disease). Recent studies showed that treatment with donepezil reduced production of inflammatory cytokines in PBMCs (peripheral blood mononuclear cells). It was also reported that musclederived inflammatory cytokines play a critical role in neovascularization in a hindlimb ischaemia model. We sought to determine whether donepezil affects angiogenesis. A hindlimb ischaemia model was created by unilateral femoral artery ligation. Blood flow recovery examined by laser Doppler perfusion imaging and capillary density by immunohistochemical staining of CD31-positive cells in the ischaemic hindlimb were significantly decreased in donepezil- and physostigmine-treated mice comparedwith control mice after 2 weeks. Donepezil reduced expression of IL (interleukin)-1β and VEGF (vascular endothelial growth factor) in the ischaemic hindlimb. Intramuscular injections of IL-1β to the ischaemic hindlimb reversed the donepezil-induced VEGF down-regulation and the anti-angiogenic effect. Hypoxia induced IL-1β expression in C2C12 myoblast cells, which was inhibited by pre-incubation with ACh (acetylcholine) or LY294002, a PI3K (phosphoinositide 3-kinase) inhibitor. Donepezil inhibited phosphorylation of Akt [also known as PKB (protein kinase B)], a downstream kinase of PI3K, in the ischaemic hindlimb. These findings suggest that cholinergic stimulation by acetylcholinesterase inhibitors suppresses angiogenesis through inhibition of PI3K-mediated IL-1β induction, which is followed by reduction of VEGF expression. Acetylcholinesterase inhibitor may be a novel anti-angiogenic therapy.

AB - Donepezil {(RS)-2-[(1-benzyl-4-piperidyl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one} is a reversible acetylcholinesterase inhibitor and used for treatment of patients with AD (Alzheimer's disease). Recent studies showed that treatment with donepezil reduced production of inflammatory cytokines in PBMCs (peripheral blood mononuclear cells). It was also reported that musclederived inflammatory cytokines play a critical role in neovascularization in a hindlimb ischaemia model. We sought to determine whether donepezil affects angiogenesis. A hindlimb ischaemia model was created by unilateral femoral artery ligation. Blood flow recovery examined by laser Doppler perfusion imaging and capillary density by immunohistochemical staining of CD31-positive cells in the ischaemic hindlimb were significantly decreased in donepezil- and physostigmine-treated mice comparedwith control mice after 2 weeks. Donepezil reduced expression of IL (interleukin)-1β and VEGF (vascular endothelial growth factor) in the ischaemic hindlimb. Intramuscular injections of IL-1β to the ischaemic hindlimb reversed the donepezil-induced VEGF down-regulation and the anti-angiogenic effect. Hypoxia induced IL-1β expression in C2C12 myoblast cells, which was inhibited by pre-incubation with ACh (acetylcholine) or LY294002, a PI3K (phosphoinositide 3-kinase) inhibitor. Donepezil inhibited phosphorylation of Akt [also known as PKB (protein kinase B)], a downstream kinase of PI3K, in the ischaemic hindlimb. These findings suggest that cholinergic stimulation by acetylcholinesterase inhibitors suppresses angiogenesis through inhibition of PI3K-mediated IL-1β induction, which is followed by reduction of VEGF expression. Acetylcholinesterase inhibitor may be a novel anti-angiogenic therapy.

UR - http://www.scopus.com/inward/record.url?scp=84862337182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862337182&partnerID=8YFLogxK

U2 - 10.1042/CS20110633

DO - 10.1042/CS20110633

M3 - Article

C2 - 22369073

AN - SCOPUS:84862337182

VL - 123

SP - 241

EP - 249

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - 4

ER -